Investor Presentation Q1 2023

93 Investor presentation First three months of 2023 Novo NordiskⓇ In phase 2, semaglutide showed significant improvements in NASH resolution Semaglutide showed resolution of NASH with no worsening of fibrosis versus placebo in the phase 2 trial¹ Proportion of patients 100% Semaglutide showed numerical improvements in fibrosis and fewer patients had progression of fibrosis vs placebo in phase 2 trial¹ Proportion of patients with improvements in fibrosis 100% Proportion of patients with progression of fibrosis 100% 80% 60% 40% 22.9% 20% * * 47.3% 46.9%* 0% Placebo 0.1 mg 0.2 mg semaglutide once-daily 80% * 66.7% 80% 60% 60% 47.3% 47.8% 40% 35.9% 34.3% 40% 21.4% 20% 20% 10.8% 9.4% * 5.8% 0% 0% 0.4 mg Placebo 0.1 mg 0.2 mg 0.4 mg Placebo 0.1 mg 0.2 mg 0.4 mg semaglutide once-daily semaglutide once-daily Note: *statistically significant at 72 weeks (p<0.05 vs placebo). ¹Based on a complete case analysis, using people with an evaluable biopsy at end of trial. Analysis included patients with fibrosis stage 1, 2, or 3 at baseline. Data is from the semaglutide in NASH phase 2 trial. NASH: non-alcoholic steatohepatitis

View entire presentation